Publications & Reports

Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice.

Lees CJ, Apostolopoulos V, Acres B, Ramshaw I, Ramsay A, Ong CS, McKenzie IF
The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia.

Abstract

Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8(+) cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.

Publication

  • Journal: Vaccine
  • Published: 15/09/2000
  • Volume: 19
  • Issue: 2-3
  • Pagination: 158-162